BiotechTube

Valette (Dienogest/EE30, BAY86-5038) + Valette (Dienogest/EE30, BAY86-5038)

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Oral Contraceptive

Conditions

Oral Contraceptive

Trial Timeline

Jun 1, 2003 → Feb 1, 2005

NCT ID
NCT00302666

About Valette (Dienogest/EE30, BAY86-5038) + Valette (Dienogest/EE30, BAY86-5038)

Valette (Dienogest/EE30, BAY86-5038) + Valette (Dienogest/EE30, BAY86-5038) is a phase 3 stage product being developed by Bayer for Oral Contraceptive. The current trial status is completed. This product is registered under clinical trial identifier NCT00302666. Target conditions include Oral Contraceptive.

What happened to similar drugs?

5 of 20 similar drugs in Oral Contraceptive were approved

Approved (5) Terminated (2) Active (14)
❌AL001 + Placebo + Open label - AL001AlectorPhase 3
🔄Micafungin + FluconazoleAstellas PharmaPhase 3
🔄micafungin + caspofunginAstellas PharmaPhase 3
🔄Erlotinib + PlaceboAstellas PharmaPhase 3
✅AmifostineSun PharmaceuticalApproved
🔄Teriparatide 20 mcgEli LillyPhase 3
✅tramadol hydrochloride + acetaminophenJohnson & JohnsonApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00302666Phase 3Completed

Competing Products

20 competing products in Oral Contraceptive

See all competitors
ProductCompanyStageHype Score
AL001 + Placebo + Open label - AL001AlectorPhase 3
22
AL001AlectorPhase 2
25
AG013OragenicsPhase 2
17
LP-10 (Liposomal Tacrolimus)Lipella PharmaceuticalsPhase 2
29
Micafungin + FluconazoleAstellas PharmaPhase 3
40
micafungin + caspofunginAstellas PharmaPhase 3
40
Erlotinib + PlaceboAstellas PharmaPhase 3
40
AmifostineSun PharmaceuticalApproved
35
exenatide + Other antidiabetic therapiesEli LillyPre-clinical
26
Teriparatide 20 mcgEli LillyPhase 3
40
LY3884963 + Methylprednisolone + Optional Sirolimus + Optional PrednisoneEli LillyPhase 1/2
36
Baricitinib 4 milligram Oral TabletEli LillyPhase 2
39
tramadol hydrochloride + acetaminophenJohnson & JohnsonApproved
43
Essential oils + 0.2% chlorhexidine + Sterile waterJohnson & JohnsonApproved
43
galantamine hydrobromideJohnson & JohnsonPhase 2
35
HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3
40
Camrelizumab + Camrelizumanb plus TPFJiangsu Hengrui MedicinePhase 2
35
Camrelizumab plus TP + TPJiangsu Hengrui MedicinePhase 3
47
AZD1981 + Neovletta 21/28 + Placebo AZD1981AstraZenecaPhase 1
29
DurvalumabAstraZenecaPhase 1/2
36